Status:

COMPLETED

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

Lead Sponsor:

Mayo Clinic

Collaborating Sponsors:

National Cancer Institute (NCI)

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Brief Summary

RATIONALE: Studying samples of blood in the laboratory from patients with cancer receiving anastrozole may help doctors learn more about changes that occur in DNA and identify biomarkers related to ca...

Detailed Description

OBJECTIVES: * To evaluate the association of intragenic haplotypes in genes encoding proteins involved in anastrozole metabolism pathways with anastrozole steady state plasma levels in postmenopausal...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Diagnosis of breast cancer
  • Stage I, II, or III disease
  • Resected disease
  • Planning to undergo treatment with anastrozole at the clinically approved dose of 1 mg/day OR Mayo Clinic Cancer Center Rochester patient who will be enrolled on or has been enrolled on CAN-NCIC-MA27 and has not started taking the study medication (anastrozole or exemestane)
  • Hormone receptor status:
  • Estrogen receptor-positive and/or progesterone receptor-positive primary tumor
  • PATIENT CHARACTERISTICS:
  • Female
  • Postmenopausal
  • Able to complete questionnaires alone or with assistance
  • PRIOR CONCURRENT THERAPY:
  • More than 6 months since prior endocrine therapy, except tamoxifen
  • No other prior aromatase inhibitors (e.g., letrozole or exemestane)
  • No prior ovarian function suppression with surgery or radiotherapy, ovarian ablation, or luteinizing hormone-releasing hormone analogues (e.g., goserelin) as treatment for cancer

Exclusion

    Key Trial Info

    Start Date :

    July 1 2005

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    March 1 2010

    Estimated Enrollment :

    1000 Patients enrolled

    Trial Details

    Trial ID

    NCT00283608

    Start Date

    July 1 2005

    End Date

    March 1 2010

    Last Update

    May 16 2011

    Active Locations (4)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (4 locations)

    1

    Mayo Clinic in Arizona

    Scottsdale, Arizona, United States, 85259-5499

    2

    Mayo Clinic in Florida

    Jacksonville, Florida, United States, 32224

    3

    Mayo Clinic

    Rochester, Minnesota, United States, 55905

    4

    M. D. Anderson Cancer Center at University of Texas

    Houston, Texas, United States, 77030-4009

    Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer | DecenTrialz